Signals

Two oral GLP-1s approved in four months.

The access barrier just dropped. More employees will seek treatment.

That is good.

Here is what the data has taught me about what happens next.

What Medications Alone Cannot Do

I have worked with some of the largest employers in the country on workforce health. What I am watching right now is an inflection point that most benefits strategies are not yet built for.

Medications alone do not:

  • Preserve muscle mass
  • Build lasting metabolic habits
  • Prevent regain when discontinued

Real-world data shows only about 14% of patients remain on GLP-1 therapy at three years without structured support. When they stop, the weight returns. The cost was already paid.

What the Employers Navigating This Well Are Doing Differently

They are not simply expanding formulary access.

They are building something around the medication:

  • Physician-led support
  • Risk stratification
  • Outcome tracking

The structure is what converts spend into return.

GLP-1s increase cost when unmanaged. They reduce cost when deployed inside a system.

The Right Question for Benefits Leaders Right Now

It is not whether to cover these medications.

It is how to build the ecosystem that makes them work.

This is the conversation I think benefits leaders need to be having right now — before the utilization curve arrives and the infrastructure isn't there to meet it.

Is your benefits strategy built for what comes after the prescription?